ADC linker chemistry

01Overview and value chain#

Markers EC: FDA/EMA/NMPA oncology approval frameworks for antibody-drug conjugates | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)

An antibody-drug conjugate is three drugs in one molecule — the antibody that finds the tumor, the cytotoxic payload that kills it, and the linker that must keep them married in circulation and divorce them at the target. The linker is where the engineering lives: too stable and the payload never releases; too labile and systemic toxicity mirrors chemotherapy. Modern chemistry answers with cleavable linkers tuned to tumor-endogenous triggers (cathepsin-cleavable dipeptides, acid-labile hydrazones, reducible disulfides) and with site-specific conjugation that puts the payload at engineered positions instead of random lysines — a shift that tightens the drug-to-antibody ratio distribution and narrows the safety margin. Manufacturing the molecule means handling payloads at occupational exposure limits of nanograms per cubic meter, which is why the CDMO layer around ADC chemistry builds high-potency suites as specialized as the chemistry itself. The corpus’s ledger evidence tracks the maturity: a Chinese CRDMO runs payload GMP from gram to beyond 10 kg at an OEL of 10 ng/m³ and fills drug product at up to 15 million doses per year; a US platform company runs cell-free, site-specific conjugation with commercial manufacturing outsourced to 4,500 L CMO batches; and a Yantai commercial-stage developer holds NMPA approvals for a disitamab-vedotin ADC while expanding capacity toward 80,000 L.

Key directions of ADC linker chemistry:

1. Site-specific conjugation (Homogeneous DAR): engineered cysteine, glycan remodeling and enzymatic coupling replace random lysine attachment; WuXi XDC’s WuXiDARx platform builds on interchain cysteine sites for flexible drug-to-antibody ratios with a simplified CMC process.
2. Cell-free conjugation platforms (XpressCF Route): Sutro Biopharma’s cell-free expression on E. coli and CHO lysate integrates non-natural amino acids for site-specific payload placement, with reactors scaled to thousands of litres.
3. High-potency payload manufacturing (HP Payload GMP): payload and linker GMP from gram to >10 kg at OEL 10 ng/m³ (OEB-5), with conjugation production from 5 L to 2,000 L integrated alongside antibody drug substance in the same building.
4. Commercial ADC products (Approved Conjugates): RemeGen’s disitamab vedotin holds NMPA approvals in gastric cancer, urothelial cancer and advanced breast cancer, with H1 2026 revenue of RMB 5,850.2 million across its portfolio.

Sectoral value chain#

[antibody candidate] ──> [payload/linker synthesis] ──> [conjugation]
                                                              │
                                                    (DAR homogeneity control)
                                                              │
                                                              ▼
[approved therapy] <── [fill-finish, clinic] <── [analytics, batch release]

Value chain levels#

Cross-cutting technologies of the sector:

• High-potency containment suites (OEB-5 Facilities): isolator lines and air-handling that make nanogram-exposure payloads manufacturable.
• Process analytics for conjugates (DAR Analytics): HIC and LC-MS methods that read drug-to-antibody distribution batch by batch.
• Bioconjugate platform extension (Beyond-ADC Modalities): the same conjugation stack extended to antibody-oligonucleotide, antibody-chelator and degrader conjugates.

02US#

The US concentrates platform invention — site-specific conjugation and cell-free expression — while manufacturing leans on CDMO capacity at home and abroad.

Cell-free conjugation platforms, outsourced GMP batches, FDA oncology pathway#

• Sutro Biopharma (South San Francisco): founded 2003, 134 employees as of March 2026; XpressCF cell-free expression on E. coli/CHO lysate for antibodies and ADCs, with San Carlos operations wound down toward a 2026 exit and commercial-scale batches run externally at 4,500 L.
• CDMO manufacturing layer: external manufacturing at partners such as Boehringer Ingelheim’s facilities carries commercial-scale demand that US platform companies no longer build for themselves.
• FDA as reference regulator: the oncology CDx-and-drug approval framework the sector’s Chinese and European filings benchmark against.

03CN#

China industrialized ADC manufacturing fastest, pairing integrated CRDMO capacity with domestic approvals that no longer wait for Western benchmarks.

WuXi XDC CRDMO scale, NMPA-approved conjugates, capacity build-out#

• WuXi XDC: the ADC-focused CRDMO spun out of WuXi Biologics and WuXi AppTec — payload GMP to >10 kg at OEB-5, 5–2,000 L conjugation, drug-product filling up to 15 million doses per year, GMP compliance across FDA, EMA and NMPA frameworks, a Singapore dual-sourcing site planned for 2026, and a Hong Kong listing (2268) with rapidly growing revenue as the global ADC CRDMO leader.
• RemeGen (Yantai): disitamab vedotin approved in China for gastric cancer, urothelial cancer and advanced breast cancer; telitacicept approved for SLE, RA and gMG; 3,146 employees and capacity of 36,000 L (2021) expanding toward 80,000 L; H1 2026 revenue of RMB 5,850.2 million.
• Capacity as strategy: the 36,000-to-80,000 L expansion race mirrors global ADC demand — capacity, not molecules, is the sector’s near-term bottleneck.

04EU#

Europe’s role is regulatory reference and manufacturing partner: EMA filings and European CDMO suites carry global ADC programs that discovery-started elsewhere.

EMA oncology framework, European high-potency CDMO suites, dual-sourcing strategy#

• EMA as second regulator: global ADC programs file EMA alongside FDA and NMPA — the WuXi XDC compliance set spans all three, the standard posture for a commercial conjugate.
• European CDMO batches: 4,500 L commercial batches at Boehringer Ingelheim facilities show where US platform companies’ molecules actually get made.
• Singapore dual-sourcing as template: a 2026 operational Singapore site built to support global dual-sourcing is the capacity-resilience pattern European buyers increasingly demand.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack runs from containment chemistry to the fill line, and its innovations are mostly about controlling distribution — of payload positions, of exposure, of batch variability.

1. Site-specific conjugation chemistry (Homogeneous ADCs):
   • engineered interchain cysteines and enzymatic coupling deliver defined drug-to-antibody ratios instead of statistical mixtures.
   • case: WuXiDARx — flexible DAR on native IgG1 backbones with a simplified CMC process.
2. Cell-free expression for conjugation-ready antibodies (Lysate Platforms):
   • open-cell lysate systems incorporate non-natural amino acids that give conjugation chemistry orthogonal handles.
   • case: Sutro’s XpressCF on E. coli and CHO lysate, scaled to thousand-litre reactors with commercial batches at external CDMOs.
3. High-potency manufacturing chain (OEB-5 to Fill-Finish):
   • cryogenic and high-containment reactions handle payloads at 10 ng/m³ occupational exposure, with prep-HPLC isolation and lyophilization before conjugation.
   • case: gram-to->10 kg payload GMP and 2R-vial filling up to 15 million doses per year on one integrated CRDMO site.

07Value chains and production pipelines#

Industrial pipeline of an ADC manufacturing campaign (OEB-5 containment regime)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Antibody production    │ ───> │ 2. Payload-linker GMP     │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Analytics and release  │ <─── │ 3. Conjugation            │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Fill-finish            │ ───> │ 6. Multi-region supply    │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Antibody production

The mAb intermediate is manufactured in 500–2,000 L cell culture and drug substance is brought into the same building as conjugation to cut hold steps.

Stage 2: Payload-linker GMP

Cytotoxic linker-payload is synthesized under OEB-5 containment from gram to >10 kg scale, with HP hydrogenation and cryogenic chemistry behind isolator lines.

Stage 3: Conjugation

Payload is coupled to the antibody at engineered or interchain cysteine sites across 5–2,000 L reactors, holding the drug-to-antibody ratio inside its registered window.

Stage 4: Analytics and batch release

HIC and LC-MS methods verify DAR distribution, residual free payload and aggregation before any batch moves downstream.

Stage 5: Fill-finish

Low-hold-up vial lines (2R–50R) and lyophilizers pack drug product — up to 15 million doses per year on one integrated line set.

Stage 6: Multi-region supply

Released product ships under FDA, EMA and NMPA compliance, with Singapore dual-sourcing capacity planned to de-risk single-region supply by 2026.